These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 26317311)

  • 1. Application of HER2 CISH pharmDX for DNA Ploidy Determination.
    He M; Pasquariello T; Steinhoff M
    Appl Immunohistochem Mol Morphol; 2016 Aug; 24(7):465-9. PubMed ID: 26317311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
    Pedersen M; Rasmussen BB
    Diagn Mol Pathol; 2009 Jun; 18(2):96-102. PubMed ID: 19430295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of Chromogenic In Situ Hybridization to Assess Ploidy in the Diagnosis of Hydatidiform Mole.
    Kunesh JP; Kunesh JG; Jorgensen RJ; Corral CD; Blakey JD
    Am J Clin Pathol; 2016 Jul; 146(1):125-31. PubMed ID: 27402609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
    Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
    Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization].
    Bai YF; Ren GP; Wang B; Teng LS; Liu X
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):161-5. PubMed ID: 20450761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visualization of FISH Probes by dual-color chromogenic in situ hybridization.
    Hoff K; Jørgensen JT; Müller S; Røngaard E; Rasmussen O; Schønau A
    Am J Clin Pathol; 2010 Feb; 133(2):205-11. PubMed ID: 20093229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
    Li-Ning-T E; Ronchetti R; Torres-Cabala C; Merino MJ
    Int J Surg Pathol; 2005 Oct; 13(4):343-51. PubMed ID: 16273190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.
    Hwang CC; Pintye M; Chang LC; Chen HY; Yeh KY; Chein HP; Lee N; Chen JR
    Histopathology; 2011 Nov; 59(5):984-92. PubMed ID: 22092410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
    Shen DH; Wang FH; Yu YZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of hydatidiform moles using p57 immunohistochemistry and HER2 fluorescent in situ hybridization.
    LeGallo RD; Stelow EB; Ramirez NC; Atkins KA
    Am J Clin Pathol; 2008 May; 129(5):749-55. PubMed ID: 18426735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fluorescence in situ hybridization, p57 immunostaining, flow cytometry, and digital image analysis for diagnosing molar and nonmolar products of conception.
    Kipp BR; Ketterling RP; Oberg TN; Cousin MA; Plagge AM; Wiktor AE; Ihrke JM; Meyers CH; Morice WG; Halling KC; Clayton AC
    Am J Clin Pathol; 2010 Feb; 133(2):196-204. PubMed ID: 20093228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.
    Yan B; Choo SN; Mulyadi P; Srivastava S; Ong CW; Yong KJ; Putti T; Salto-Tellez M; Lim GS
    J Clin Pathol; 2011 Dec; 64(12):1097-101. PubMed ID: 21896578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.
    Hauser-Kronberger C; Dandachi N
    J Mol Histol; 2004 Aug; 35(6):647-53. PubMed ID: 15614619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.
    Di Palma S; Collins N; Bilous M; Sapino A; Mottolese M; Kapranos N; Schmitt F; Isola J
    J Clin Pathol; 2008 Jun; 61(6):757-60. PubMed ID: 18326010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p57KIP2 immunohistochemistry in early molar pregnancies: emphasis on its complementary role in the differential diagnosis of hydropic abortuses.
    Merchant SH; Amin MB; Viswanatha DS; Malhotra RK; Moehlenkamp C; Joste NE
    Hum Pathol; 2005 Feb; 36(2):180-6. PubMed ID: 15754295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
    Tanner M; Gancberg D; Di Leo A; Larsimont D; Rouas G; Piccart MJ; Isola J
    Am J Pathol; 2000 Nov; 157(5):1467-72. PubMed ID: 11073807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.